Gilead Sciences Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for their HIV treatment, Biktarvy. The approval expands the use of Biktarvy to include people with HIV who have a history of antiretroviral treatment, are not virologically suppressed, and are restarting therapy. This new indication addresses a significant public health need by offering a treatment option for individuals who have interrupted their HIV care and are not currently achieving viral suppression. The decision was based on robust evidence from studies demonstrating Biktarvy's effectiveness in achieving rapid and durable viral suppression, as well as its strong safety profile.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.